16-30 of 32
The Integral Role of GnRH Antagonists in the Management of Endometriosis
MinuteCE®The Integral Role of GnRH Antagonists in the Management of Endometriosis
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Pre- and Postoperative Use of GnRH Antagonists
MinuteCE®Pre- and Postoperative Use of GnRH Antagonists
Lee P. Shulman, MD, FACMG, FACOG
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
MinuteCE®Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
MinuteCE®Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG
Linda Bradley, MD
Samantha Denäe
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
MinuteCE®Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Considerations for the Diagnosis of Endometriosis
MinuteCE®Clinical Considerations for the Diagnosis of Endometriosis
Linda Bradley, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
- advertisement
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
MinuteCE®It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
Linda Bradley, MD
Melissa Simon, MD
Casey Joe Hinds
Lee P. Shulman, MD, FACMG, FACOG
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
Linda Bradley, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Melissa Simon, MD
Samantha Denäe
Casey Joe Hinds
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
CME/CEInnovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
Kara B. Markham, MD
Kenneth J. Moise Jr., MD
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
CME/CEWhy Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
Lee P. Shulman, MD, FACMG, FACOG
Roberto Romero, MD, DMedSci
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
CME/CEParallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
Lee P. Shulman, MD, FACMG, FACOG
Alexandra Benachi, MD, PhD
Julien Zuber, MD, PhD
Alloimmune Neutropenia of the Fetus and Newborn
CME/CEAlloimmune Neutropenia of the Fetus and Newborn
Lee P. Shulman, MD, FACMG, FACOG
Masja de Haas, MD, PhD
- advertisement
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
CME/CEEmploying Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Robert L. Coleman, MD, FACOG, FACS
Susana Campos, MD, MPH
Domenica Lorusso, MD, PhD
Alloimmune Thrombocytopenia in the Fetus and Newborn
CME/CEAlloimmune Thrombocytopenia in the Fetus and Newborn
Lee P. Shulman, MD, FACMG, FACOG
James B. Bussel, MD
Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization
CME/CETargeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization
Lee P. Shulman, MD, FACMG, FACOG
Kenneth J. Moise Jr., MD
